Human T-lymphotropic virus type-1 (HTLV-1) is a human retrovirus that causes HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukaemia (ATL). A higher viral load in individuals with HTLV-1 infection increases their risk of developing HAM/TSP and ATL. Moreover, the high proviral load is associated with the clinical progression of HAM/TSP. Reduction of the number of HTLV-1-infected cells is therefore crucial for preventing and treating HTLV-1-associated diseases. Recently, fucoidan, a complex sulphated polysaccharide derived from marine seaweed, has been demonstrated to exert inhibitory effects on HTLV-1 infection in vitro. In this study, we examined the in vivo effects of fucoidan on HTLV-1 infection.
Methods
In this single-centre open-label trial, 13 patients with HAM/TSP were treated with 6 g fucoidan daily for 6–13 months. The HTLV-1 proviral DNA load and frequencies of HTLV-1-specific CD8+ T-cells, natural killer cells, invariant natural killer T-cells and dendritic cells in the peripheral blood were analysed. Furthermore, the in vitro inhibitory effect of fucoidan on cell-to-cell HTLV-1 infection was examined by using luciferase reporter cell assays.
Results
Fucoidan inhibited the cell-to-cell transmission of HTLV-1 in vitro. Furthermore, fucoidan therapy resulted in a 42.4% decrease in the HTLV-1 proviral load without affecting the host immune cells. During the treatment, no exacerbation was observed. Four patients with HAM/TSP developed diarrhoea, which improved immediately after stopping fucoidan administration.
Conclusions
Fucoidan is a new potential therapeutic agent for the prevention and treatment of HTLV-1-associated diseases.
References
1.
de ThéG., BomfordR.An HTLV-I vaccine: why, how, for whom?AIDS Res Hum Retroviruses1993; 9: 381–386.
2.
UchiyamaT., YodoiJ., SagawaK., TakatsukiK., UchinoH.Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood1977; 50: 481–492.
3.
GessainA., BarinF., VernantJ.C.Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet1985; 2: 407–410.
4.
OsameM., UsukuK., IzumoS.HTLV-I associated myelopathy, a new clinical entity. Lancet1986; 1: 1031–1032.
5.
NagaiM., UsukuK., MatsumotoW.Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol1998; 4: 586–593.
6.
NagaiM., YamanoY., BrennanM.B., MoraC.A., JacobsonS.Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax -specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol2001; 50: 807–812.
7.
YamanoY., NagaiM., BrennanM.Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/ TSP). Blood2002; 99: 88–94.
8.
OkayamaA., StuverS., MatsuokaM.Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer2004; 110: 621–625.
9.
MahonyM.C., OehningerS., ClarkG.F.Fucoidan inhibits the zona pellucid-induced acrosome reaction in human spermatozoa. Contraception1991; 44: 657–665.
10.
BabaM., SnoeckR., PauwelsR., de ClercqE.Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother1988; 32: 1742–1745.
11.
ZacharopoulosV.R., PhillipsD.M.Cell-mediated HTLV-1 infection of a cervix-derived epithelial cell line. Microb Pathog1997; 23: 225–233.
12.
RomanosM.T.V., Andrada-SerpaM.J., MouraoP.A.S.A sulphated fucan from the Laminaria abyssalis inhibits the human T cell lymphotropic virus type 1- induced syncytium formation in HeLa cells. Antivir Chem Chemother2002; 13: 219–221.
13.
HanejiK., MatsudaT., TomitaM.Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutr Cancer2005; 52: 189–201.
14.
YoshidaA., PiroozmandA., SakuraiA.Establishment of a biological assay system for human retroviral protease activity. Microbes Infect2005; 7: 820–824.
15.
FukushimaN., NakamuraT., NishiuraY., IdaH., AramakiT., EguchiK.HTLV-I production based on activation of integrin/ ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. Intervirology2008; 51: 123–129.
16.
OsameM.Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In BlattnerW.A. (Editor). Human Retrovirology: HTLV.New York: Raven Press1990; pp. 191–197.
17.
NakagawaM., IzumoS., IjichiS.HTLV-I associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol1995; 1: 50–61.
18.
NagaiM., KubotaR., GretenT.F.Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis2001; 183: 197–205.
19.
IgakuraT., StinchcombeJ.C., GoonP.K.Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science2003; 299: 1713–1716.
20.
BanghamC.R.HTLV-1 infection: role of CTL efficiency. Blood2008; 112: 2176–2177.
21.
AzakamiK., SatoT., ArayaN.Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood2009; 114: 3208–3215.
22.
BanghamC.R., OsameM.Cellular immune response to HTLV-1. Oncogene2005; 24: 6035–6046.
23.
OhU., YamanoY., MoraC.A.Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol2005; 57: 526–534.
24.
NomotoM., UtatsuY., SoejimaY., OsameM.Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology1991; 41: 457.
25.
TakenouchiN., YamanoY., UsukuK., OsameM., IzumoS.Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol2003; 9: 29–35.
26.
TaylorG.P., TosswillJ.H., MatutesE.Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr1999; 22: 92–100.
27.
NoseH., SaitoM., UsukuK.Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load. J Neurovirol2006; 12: 171–177.
28.
YamanoY., CohenC.J., TakenouchiN.Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med2004; 199: 1367–1377.
29.
YamanoY., ArayaN., SatoT.Abnormally high levels of virus-infected IFN-gamma+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE2009; 4: e6517.
30.
SaitoM., NakagawaM., KasedaS.Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis2004; 189: 29–40.
31.
NishiuraY., NakamuraT., FukushimaN.Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther2009; 14: 533–542.
32.
SonodaJ., KoriyamaC., YamamotoS.HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci2004; 95: 596–601.
33.
TaylorG.P., GoonP., FurukawaY.Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology2006; 3: 63.
34.
LiH.C., YashikiS., SonodaJ.Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res2000; 91: 34–40.
